The RAS-RAL axis in cancer: evidence for mutation-specific selectivity in non-small cell lung cancer

Sunny GUIN¹, ², Dan THEODORESCU¹, ², ³, *

¹Department of Surgery, University of Colorado, Aurora, CO 80045, USA; ²Department of Pharmacology, University of Colorado, Aurora, CO 80045, USA; ³University of Colorado Comprehensive Cancer Center, Aurora, CO 80045, USA

Activating RAS mutations are common in human tumors. These mutations are often markers for resistance to therapy and subsequent poor prognosis. So far, targeting the RAF-MEK-ERK and PI3K-AKT signaling pathways downstream of RAS is the only promising approach in the treatment of cancer patients harboring RAS mutations. RAL GTPase, another downstream effector of RAS, is also considered as a therapeutic option for the treatment of RAS-mutant cancers. The RAL GTPase family comprises RALA and RALB, which can have either divergent or similar functions in different tumor models. Recent studies on non-small cell lung cancer (NSCLC) have showed that different RAS mutations selectively activate specific effector pathways. This observation requires broader validation in other tumor tissue types, but if true, will provide a new approach to the treatment of RAS-mutant cancer patients by targeting specific downstream RAS effectors according to the type of RAS mutation. It also suggests that RAL GTPase inhibition will be an important treatment strategy for tumors harboring RAS glycine to cysteine (G12C) or glycine to valine (G12V) mutations, which are commonly found in NSCLC and pancreatic cancer.

Keywords: RAS; RAL; RAS mutation; RALBP1; non-small cell lung cancer

RAS GTPase overview

RAS is the most extensively studied GTPase[1]. It is known to regulate various cellular functions, including proliferation, survival, growth, migration, differentiation and cytoskeletal dynamics[2–4] (Figure 1). Not coincidentally, increased activities of all of these processes are required by tumor cells to promote tumor growth. Activating oncogenic RAS mutations lead to treatment resistance in various tumor models and poor patient outcomes[3, 5–9]. Three human RAS genes have been identified: HRAS, KRAS, and NRAS[1, 2]. These encode the related proteins HRAS, KRAS and NRAS, respectively, of 189 amino acids in length[1, 4]. KRAS exists as two isoforms, 4A and 4B, which are generated by alternative exon splicing[10]. These different RAS genes are well known to have differential cellular specificities and intrinsic transforming potentials[3, 4, 10].

In normal cells, RAS proteins act as molecular switches for critical cellular functions. RAS proteins are activated by upstream receptors such as receptor tyrosine kinases...
(RTKs), G-protein coupled receptors (GPCRs) and serpentine and cytokine receptors\cite{1, 4, 11}. RAS protein activity is tightly regulated by Guanine Nucleotide Exchange Factors (GEFs) and GTPase Activating Proteins (GAPs). Constitutive activation of the RAS protein, in which RAS is unable to hydrolyze GTP, leads to cancer and other diseases\cite{1, 9, 12}. Activating RAS mutations have been observed in 30% of human tumors\cite{2, 13}; KRAS is the most commonly mutated isofrom, mutated in 25%–30% of human cancers\cite{3, 13}. KRAS mutations are dominant in colorectal cancer (40%–45%), non-small cell lung cancer (NSCLC) (15%–40%) and pancreatic carcinoma (69%–95%)\cite{2, 3} and are associated with poor patient outcomes and treatment responses in these malignancies\cite{2, 3}. NRAS mutations are found in codon 12, whereas approximately 60% of NRAS mutations are found in codon 61, with 35% in codon 12\cite{2, 14}. HRAS mutations are less common (8% and 3% of all tumors, respectively)\cite{2, 13}, with melanoma harboring the most NRAS mutations at 20%–30%\cite{2, 13}.

Activating mutations occur at codons 12, 13, and 61, which are within the GTPase catalytic domain, in all three RAS isoforms\cite{14}. Approximately 80% of KRAS mutations are found in codon 12, whereas approximately 60% of NRAS mutations are found in codon 61, with 35% in codon 12\cite{2, 14}. HRAS mutations are equally divided between codons 12 and 61\cite{2, 14}. All of these activating mutations inhibit RAS GTPase activity by preventing GAP-stimulated GTP hydrolysis of GTP-bound activated RAS.

Approximately 20 downstream effectors bind to RAS-GTP and trigger signaling. RAS drives tumor growth via a number of prominent pathways, including the following: RAF-MEK-ERK\cite{15, 16}; p110 catalytic subunits (p110α, β, γ, and δ) of class I PI3K; TIAM1, a small RAC GTPase-specific GEF; RAL-specific GEFs (RALGD5, RGL, RGL2/Rlf, RGL3, RALGPS1, and RALGPS2); and phospholipase C epsilon\cite{1, 2, 16}.

**RAS mutation and cancer therapeutics**

Devising an effective treatment strategy for patients with RAS mutations has been a major challenge\cite{3, 17, 18}. However, recent attempts have been promising\cite{17, 18}. RNA interference is an interesting approach but has many technical hurdles, including the lack of an efficient delivery system, poor uptake and low gene silencing efficiency\cite{3}. The inhibition of RAS membrane localization via the inhibition of RAS farnesylation has been investigated, but this approach has failed to materialize into a therapeutic strategy due to several limitations, including toxicity, and mainly the appearance of a compensatory mechanism via geranylgeranylation\cite{2, 8, 19}.

So far, the only approach that has shown promise in treating cancer patients with RAS mutations is the targeting of its downstream signaling cascades such as RAF-MEK-ERK and PI3K-AKT\cite{12, 8, 16, 19}. Targeting these two pathways either separately or together is beneficial in preventing *in vitro* and *in vivo* progression of tumors harboring a RAS mutation\cite{2}. Currently, clinical trials are being conducted to study the therapeutic effects of MEK and PI3K inhibitors in cancer patients harboring RAS mutations\cite{20}. However, a wrinkle in this approach has appeared. Recent studies have shown that different KRAS mutations preferentially activate different downstream signaling pathways. For example, mutant KRAS with either a glycine to cysteine (G12C) or glycine to valine (G12V) mutation at codon 12 preferentially binds to RAL guanine nucleotide dissociation stimulator (RALGDS), a RAL GTPase-specific GEF, whereas KRAS harboring a glycine to aspartate mutation at codon 12 (G12D) has higher affinity for phosphatidylinositol 3-kinase (PI3K)\cite{20}. These recent studies have brought to light the need to clarify the impact of such KRAS mutations on the RAL GTPase signaling pathway.

**The RAL GTPase family and effectors**

RAL GTPase falls under the RAS family of GTPases. RAL shares a high degree of sequence similarity with the three RAS genes, hence the name RAL (RAS-like)\cite{15}. The RAL GTPase sub-family comprises the two isoforms RALA and RALB, which share high sequence homology\cite{21}. Approximately 85% of the amino acid sequences of these two isoforms are identical\cite{20}. RAL GTPase can be activated by six GEFs (RALGEFs), RALGD5, RGL, RGL2/Rlf, RGL3, RALGPS1, and RALGPS2, and inactivated by two GAPs, RALGAP1, and RALGAP2\cite{22, 23}. Four RALGEFs (RALGD5, RGL, RGL2, and RGL3) are known to directly interact with the effector binding region of GTP-bound RAS and are thus important for RAS-mediated tumorigenesis\cite{22}. RALGEFs and RAL play a dominant role in the RAS-mediated transformation of several different immortalized human cell lines, as well as in a RAS-driven tumor model\cite{24, 25}.

RAL proteins mediate various cellular activities, including filopodia formation/membrane ruffling, glycolysis, autophagy, secretion, the maintenance of polarity, apoptosis and transcription\cite{21, 26} (Figure 2). Alterations to these activities can lead to tumor invasion, metastasis, altered cellular energy levels, proliferative signaling and resistance to cell death. These activities are mediated by effectors that interact with activated (GTP-bound) RAL\cite{25}. Of all the RAL effectors, the most extensively studied are RALBP1 and the members of the exocyst complex Sec5 and Exo84\cite{26}. Other RAL effectors include Filamin, PDL1 and ZONAB\cite{28}.

RALBP1 has GAP activity for RAC/CDC42 proteins. In this way, RALBP1 is important for actin dynamics, filopodia formation and membrane ruffling\cite{26, 27, 28}, thereby contributing to cancer cell adhesion, invasion and migration. RALBP1 is critical for the migration of bladder and prostate cancer cells, which is partly independent of its interaction with RAL\cite{28}. RALBP1 is also important for endocytosis, including receptor-mediated endocytosis of proteins such as epidermal growth factor receptor, insulin receptor and transferrin receptor, through its interactions with POB1, Reps1 and AP2\cite{29, 31}. The involvement of RALBP1 in receptor endocytosis points to the prominence of RAL in signal transduction by these receptors, which regulate various cellular processes such as survival and proliferation\cite{32, 33}. RALBP1 has also been identified as a non-ABC transporter that causes resistance to chemotherapeutic drugs\cite{14}. RALBP1 is known to cause resistance to anthracycline derivatives such as doxorubicin and glutathione conjugates by increasing their efflux from cells in an ATP-
dependent manner\textsuperscript{[34–36]}. This transporter activity of RALBP1 helps to protect cancer cells from cytotoxic drugs and cellular stress\textsuperscript{[34]}. RALBP1 also induces mitochondrial fission by promoting the phosphorylation of the GTPase DRP1 by CyclinB/CDK1 and facilitating the recruitment of DRP1 to mitochondrial membranes\textsuperscript{[37]}. The absence of RALA-dependent RALBP1 activation leads to the improper segregation of mitochondria to daughter cells during cell division, resulting in improper cellular metabolic activity, including cellular ATP production, which assists cell growth\textsuperscript{[37]}. RALBP1 is also known to promote invadopodia formation upon activation by RALB\textsuperscript{[38]}. This RALBP1-dependent invadopodia formation is essential for RALB-mediated cell invasion and migration. RALBP1 ATPase function is required for invadopodia formation\textsuperscript{[38]}.

Sec5 and Exo84 are members of the exocyst complex and are responsible for targeting various secretory vesicles to specific regions of the cellular membrane\textsuperscript{[39, 40]}. This regulation of vesicular trafficking controls various complex cellular functions such as polarized membrane formation, cytokinesis, tight junction formation, and tumor cell invasion\textsuperscript{[41–44]}. RALB also interacts with Sec5 to activate the k\(b\) kinase TBK1\textsuperscript{[21, 43]}. Upon chronic RALB activation, the RALB/Sec5 effector complex, through TBK1, promotes cancer cell survival and RALB-mediated protection from apoptosis\textsuperscript{[45]}. A separate RALB/Exo84 complex activates autophagosome assembly under starvation conditions via ULK1 and Beclin1-VPS34\textsuperscript{[21, 46]}. Thus, RALB can act as a nutrient sensor by promoting autophagosome formation upon nutrient deprivation\textsuperscript{[46]}. The RALB/Exo84 complex is able to maintain the balance between cellular growth and maintenance based on nutrient availability through autophagocytosis\textsuperscript{[46]}. On the other hand, the RALA/Exo84 complex is known to regulate the morphology and polarized migration of neuronal progenitor cells. Loss of the RALA/Exo84 interaction hampers polarity in postnatal migratory neuroblasts and embryonic neurons\textsuperscript{[47]}. Thus, RALA/Exo84 can promote cellular migration by altering cell polarization\textsuperscript{[47]}.

RAL also interacts with ZONAB to regulate cellular transcription, which gives rise to cellular proliferative signaling\textsuperscript{[48]}. Upon its activation by RAS, RALA is known to complex with ZONAB and inhibit its transcription-repressing activity, thereby promoting the transcription of genes required for cellular proliferation and tumorigenesis\textsuperscript{[48]}. RALA is known to bind Filamin to regulate actin cross-linking, which ultimately results in membrane ruffling and filopodia formation\textsuperscript{[49]}. RALA is required for CDC42-mediated filopodia formation with the help of Filamin, which aids in cell invasion, adhesion, and migration\textsuperscript{[49]}. PLD1 is another important effector of RAL GTPase; PLD1 plays a role in membrane trafficking and as a signaling molecule\textsuperscript{[50]}. PLD1 is responsible for RALA-mediated mTOR pathway activation\textsuperscript{[51]}. RALA acts as a nutrient sensor and promotes protumorigenic signaling through mTOR with the help of PLD1.

**RAL in cancer**

Even though RALA and RALB have significant amino acid sequence homology, they also have some different cellular functions. RALA is important for tumor growth, whereas RALB is important for tumor metastasis and invasion\textsuperscript{[20–22, 52–54]}. However, it has also been reported a number of times that
both isoforms also have redundant functions in cancer\textsuperscript{24, 54, 55}. Increased expression and activation of the RAL isoforms are observed in various tumor types compared with normal tissues, as well as in high-stage and high-grade tumors, signifying their importance in tumorigenesis\textsuperscript{55–59}. In most cancer models, RALA has been established as the dominant RAL isoform and the main driver of tumor progression and metastasis.

In melanoma and non-small cell lung cancer (NSCLC), RALA and RALB seem to have redundant effects on tumor growth\textsuperscript{24, 55, 59, 60}. In melanoma, RALA is the dominant isoform regulating tumor growth\textsuperscript{59}. However, the RAL effectors responsible for melanoma tumor growth have not been studied\textsuperscript{59}. Male \textit{et al.} showed that RALA is important for \textit{in vitro} and \textit{in vivo} growth and invasion of NSCLC cells using only the A549 cell line as a model\textsuperscript{60}. The role of RALB in growth and invasion of the A549 NSCLC cell line was not investigated in this study\textsuperscript{60}. RALBP1 was established as the primary RALA effector in A549 cells\textsuperscript{60}. Our lab used a panel of 14 NSCLC cell lines and showed that RALA and RALB had redundant functions in NSCLC tumor growth and that RALBP1 is the primary effector driving this phenotype\textsuperscript{55}. Our lab further developed the first known RAL inhibitors and showed that these small molecule drugs inhibited the growth of NSCLC cell lines \textit{in vitro} and \textit{in vivo} by limiting the binding of RALBP1 to both RALA and RALB\textsuperscript{61}. In pancreatic cancer, RALA is important for tumor growth, whereas RALA and RALB are both required for invasion\textsuperscript{62}. The RALBP1-RAL interaction was attributed to pancreatic tumor growth and invasion\textsuperscript{54}. Phosphorylation of RALA at S194 by Aurora-A has been shown to induce pancreatic cancer growth\textsuperscript{62}. This study showed that RALA phosphorylation assists in the RALA-RALBP1 interaction and that this interaction drives pancreatic tumor growth\textsuperscript{62}. RALA and RALB have also been shown to provide protection against ionizing radiation via the effectors RALBP1 and Sec5 in pancreatic cancer cell lines\textsuperscript{63}.

Both RAL isoforms have important functions in the growth and metastasis of bladder cancer\textsuperscript{28, 64, 65}. RALA is important for the progression of hepatocellular carcinoma, colorectal cancer, chronic myeloid leukemia, squamous cell carcinoma of the skin and nerve sheath tumors\textsuperscript{57, 66–69}. RALA is also pro-migratory, assisting in the metastasis of prostate cancer to bone and aiding in the invasion of squamous cell carcinoma of the skin and renal cancers\textsuperscript{28, 68, 70, 71}. RALB, however, is important for the invasion and migration of bladder cancer, oral squamous cell carcinoma, B cells and multiple myeloma cells\textsuperscript{60, 72, 73}. RALBP1 has been identified as the main RAL effector in the majority of these tumors. RAL-driven colorectal cancer growth has been attributed to RALBP1, Sec5, and Exo84\textsuperscript{65}. Sec5 and Exo84 have been identified as important RAL effectors in squamous cell carcinoma of the skin\textsuperscript{60}. The phosphorylation of RALB at S198 by protein kinase C (PKC) is an important driver of bladder cancer growth and metastasis via promotion of the RALB-RALBP1 interaction\textsuperscript{65}. A transcriptional signature was recently developed to report cellular RAL activity levels\textsuperscript{74}. This RAL signature was predictive of cancer patient outcomes, indicating for the first time that the genes and pathways regulated by RAL are important for tumor formation and progression in cancer patients\textsuperscript{74}.

### Dependency of RAL activity on RAS mutation

Recent studies on NSCLC patient samples showed that patients carrying a glycine to cysteine (G12C) or a glycine to valine (G12V) amino acid mutation at codon 12 of KRAS have worse outcomes compared with patients carrying other KRAS mutations or wildtype KRAS\textsuperscript{20}. Interestingly, it was observed that NSCLC cell lines carrying the KRAS G12C or G12V mutation have higher RAL GTPase activities and lower PI3K/AKT pathway activation compared with cell lines carrying other KRAS mutations (Figure 3) or wildtype KRAS\textsuperscript{20}. It is known that KRAS homodimer formation is important for RAL GTPase activation via RALGDS binding to KRAS\textsuperscript{73}. Ihle \textit{et al.} used extensive molecular modeling to show that in case of the KRAS G12C mutation, the smaller cysteine residue allows for KRAS homodimer formation, RALGDS binding and subsequent RAL activation\textsuperscript{20}. Another common KRAS mutation at codon 12, the glycine to aspartate (G12D) mutation, was shown to predominantly activate the PI3K/AKT pathway\textsuperscript{20} (Figure 3). Aspartate is a bulkier amino acid than glycine, G12D mutation prevents KRAS homodimer formation via steric hindrance; thus, RAL activation is prevented\textsuperscript{20}. Since KRAS directly binds to PI3K, this pathway can be activated irrespective of KRAS dimer formation\textsuperscript{20}. Thus, different KRAS mutations help select for different downstream signaling pathways based on the properties of the oncogenic amino acid.

\begin{figure}[h]
\centering
\includegraphics[width=0.5\textwidth]{ras_pathway.png}
\caption{RAS mutations and activated pathways. Specific RAS mutations are known to activate specific downstream signaling pathways in non-small cell lung cancers.}
\end{figure}

Another study on a large group of Korean NSCLC patients showed that KRAS mutations are less common in this patient population compared with patients from Western countries\textsuperscript{76}. This observation is consistent with other studies showing that the frequencies of KRAS mutations vary with ethnicity\textsuperscript{77–80}. G12D was the most frequent KRAS transition mutation found
in the Korean patient population; this is consistent with other studies conducted on Asian NSCLC patients. The study on the Korean patients also showed high RALA membrane expression in 80% of the patient samples and high RALB membrane and cytoplasmic expression in 57% of the samples from patients carrying a KRAS mutation. Since RAL membrane expression is associated with RAL activity, we can speculate that patients with KRAS mutations have high RAL activity. The authors showed that there was no difference in RAL expression between patients harboring KRAS transition mutations, including G12D, compared to patients carrying KRAS transversion mutations such as G12C and G12V. Similarly, AKT was also not differentially expressed between patients carrying KRAS transition and transversion mutations. This study suggests that although different downstream pathways may be activated by specific KRAS mutations, the expression of these downstream signaling molecules may not change as a function of these specific KRAS mutations.

Using in vitro and in vivo functional assays, our lab established that both RAL isoforms are required for the growth of NSCLC cells carrying the KRAS G12C mutation compared with cells carrying other KRAS mutations and wild-type KRAS. We used a gene knockdown approach on multiple NSCLC cell lines that carry either wild-type KRAS or different KRAS mutations at codon 12. We showed that the loss of RALA and RALB massively inhibited anchorage-dependent and anchorage-independent growth of NSCLC cell lines carrying the KRAS G12C mutation. The loss of RALA and RALB also inhibited in vivo tumor growth with the NSCLC cell line H2122, which carries the G12C mutation. NSCLC cell lines that are wild-type for KRAS or that carry other mutations showed moderate to no inhibition in anchorage-dependent and anchorage-independent growth assays upon the loss of the RAL GTPases. Our study also showed that overexpression of the KRAS G12C mutant in the KRAS-wild-type cell line H2228 increased the activation of RAL and the dependency of the cells on RAL GTPases for anchorage-independent growth. Thus, we used detailed functional analysis to validate that the KRAS G12C mutation indeed drives tumorigenesis, predominantly via RAL GTPases. In non-smoking NSCLC patients, the probability of having a G12C or G12V KRAS mutation at codon 12 is 9% or 28%, respectively, whereas in smokers, this probability is 47% or 24%, respectively. Since KRAS G12C and G12V are the most common RAS mutations found in NSCLC, these studies point to the importance of RAL in driving tumor growth downstream of KRAS in NSCLC.

KRAS mutations are also frequently found in pancreatic and colorectal cancers. Approximately 90% of pancreatic cancer patients have a KRAS mutation at codon 12, with glycine to aspartate or arginine (G to D or A) mutations being the most frequent. In pancreatic cancers, RAL GTPase was shown to be required for in vivo metastatic growth of tumors driven by the KRAS G12V mutation, pointing to the dependency of these cancers that carry this specific KRAS mutations on the RAL pathway. KRAS mutations at codon 12, predominantly glycine to aspartate or valine (G to D or V) mutations, are also frequent in colorectal cancers. However, the role of RAL in colorectal cancer with respect to different KRAS mutations is unclear. Higher RAL GTPase activation was also observed in bladder cancer cell lines carrying the G12V HRAS mutation compared with cell lines that either are wild-type for RAS or carry other RAS mutations. Bladder cancers have a low to medium RAS mutation frequency, but 60% of the total RAS (either KRAS or HRAS) mutations present are G12V mutations, pointing to a potential dependence on the RAL signaling pathway in the majority of RAS-mutant tumors. Based on the currently available information in NSCLC, the dependency of pancreatic, colorectal and bladder tumors carrying specific RAS mutations on RAL or other downstream pathways requires investigation.

Conclusion

Drugs against the PI3K/AKT and RAF-MEK-ERK pathways are used for the treatment of patients carrying RAS mutations. RAL GTPase has not been explored as a treatment target for cancer patients harboring RAS mutations. The only reason for this is the lack of RAL GTPase inhibitors. The recent discovery that different RAS mutations specifically activate different downstream signaling pathways stresses the need for personalized treatment strategies for patients that are stratified based on their RAS mutation status. These recent findings denote that RAL GTPase is a potential drug target for the treatment of cancer patients carrying specific RAS mutations. For example, we expect that NSCLC patients carrying KRAS G12C or G12V mutations would respond to treatment with a RAL inhibitor, whereas patients carrying KRAS G12D mutations should be treated with a PI3K inhibitor. This recent observation, predominantly made in NSCLC, also calls for a comprehensive investigation in other tumor types to validate that specific RAS mutations drive specific signaling pathways. We expect that targeted therapy against RAL GTPase will be vital in the treatment of cancer patients because KRAS G12C and G12V mutations are abundant in NSCLC as well as colorectal and pancreatic cancers.

Abbreviations

NSCLC, non-small cell lung cancer; GEF, guanine nucleotide exchange factor; GAP, GTPase-activating proteins; RTK, receptor tyrosine kinase; PI3K, phosphatidylinositol 3-kinase.

References

1. Takai Y, Sasaki T, Matozaki T. Small GTP-binding proteins. Physiol Rev 2001; 81: 153–208.
2. Takashima A, Faller DV. Targeting the RAS oncogene. Expert Opin Ther Targets 2013; 17: 507–31.
3. Chetty R, Govender D. Gene of the month: KRAS. J Clin Pathol 2013; 66: 548–50.
4. Symons M, Takai Y. Ras GTPases: singing in tune. Sci STKE 2001; 2001: pe1.
5. Tan C, Du X. KRAS mutation testing in metastatic colorectal cancer. World J Gastroenterol 2012; 18: 5171–80.
6. Martin P, Leighl NB, Tsao MS, Shepherd FA. KRAS mutations as
prognostic and predictive markers in non-small cell lung cancer. J Thorac Oncol 2013; 8: 530–42.
7 di Magliano MP, Logsdon CD. Roles for KRAS in pancreatic tumor development and progression. Gastroenterology 2013; 144: 1220–9.
8 Sacco E, Spinelli M, Vanoni M. Approaches to Ras signaling modulation and treatment of Ras-dependent disorders: a patent review (2007—present). Expert Opin Ther Pat 2012; 22: 1263–87.
9 Ward AF, Braun BS, Shannon KM. Targeting oncogenic Ras signaling in hematologic malignancies. Blood 2012; 120: 3397–406.
10 Drosten M, Dhawahir A, Sum EY, Urosevic J, Lechuga CG, Esteban LM, et al. Genetic analysis of Ras signaling pathways in cell proliferation, migration and survival. EMBO J 2010; 29: 1091–104.
11 Matozaki T, Nakanishi H, Takai Y. Small G-protein networks: their crosstalk and signal cascades. Cell Signal 2010; 12: 515–24.
12 Cherfils J, Zeghouf M. Regulation of small GTPases by GEFs, GAPs, and GDIs. Physiol Rev 2013; 93: 269–309.
13 Fernandez-Medarde A, Santos E. Ras in cancer and developmental diseases. Genes Cancer 2011; 2: 344–58.
14 Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer. Cancer Res 2012; 72: 2457–67.
15 Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer 2003; 3: 93–106.
16 Rajalingam K, Schreck R, Rapp UR, Albert S. Ras oncogenes and Ral GTPases in tumorigenesis: emerging from the darkness. Nat Rev Cancer 2003; 3: 107–19.
17 Ostrem JM, Peters U, Sofis ML, Wells JA, Shokat KM. K-Ras (G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 2013; 503: 548–51.
18 Patgiri A, Yadav KK, Arora PS, Bar-Sagi D. An orthosteric inhibitor of the Ras-Sos interaction. Nat Chem Biol 2011; 7: 585–7.
19 Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003; 3: 11–22.
20 Ihle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst 2010; 102: 228–39.
21 Kashatus DF. Raf GTAPases in tumorigenesis: emerging from the shadows. Exp Cell Res 2013; 319: 2337–42.
22 Feig LA. Raf-GTAPases: approaching their 15 minutes of fame. Trends Cell Biol 2003; 13: 419–25.
23 Vigil D, Martin TD, Williams F, Yeh JJ, Campbell SL, Der CJ. Aberrant overexpression of the Rgl2 Ral small GTAPase-specific guanine nucleotide exchange factor promotes pancreatic cancer growth through Ral-dependent and Ral-independent mechanisms. J Biol Chem 2010; 285: 34729–40.
24 Peschard P, McCarthy A, Leblanc-Dominguez V, Yeo M, Guichard S, Stamp G, et al. Genetic deletion of RALA and RALB small GTAPases reveals redundant functions in development and tumorigenesis. Curr Biol 2012; 22: 2063–8.
25 Lim KH, Baines AT, Fiodalisi JJ, Shipitsin M, Feig LA, Cox AD, et al. Activation of RaLα is critical for Ras-induced tumorigenesis of human cells. Cancer Cell 2005; 7: 533–45.
26 Bodemann BO, White MA. Raf GTAPases and cancer: linchpin support of the tumorigenic platform. Nat Rev Cancer 2008; 8: 133–40.
27 Ikeda M, Ishida O, Hinoi T, Kishida S, Kikuchi A. Identification and characterization of a novel protein interacting with Ral-binding protein 1, a putative effector protein of Ral. J Biol Chem 1998; 273: 814–21.
28 Wu Z, Owens C, Chandra N, Popovic K, Conaway M, Theodorescu D. RafBP1 is necessary for metastasis of human cancer cell lines. Neoplasia 2010; 12: 1003–12.
29 Yamaguchi A, Urano T, Goi T, Feig LA. An Eps homology (EH) domain protein that binds to the Ral-GTAPase target, RafBP1. J Biol Chem 1997; 272: 31230–4.
30 Nakashima S, Morinaka K, Koyama S, Ikeda M, Kishida M, Okawa K, et al. Small G protein Raf and its downstream molecules regulate endocytosis of EGF and insulin receptors. EMBO J 1999; 18: 3629–42.
31 Jullien-Flores V, Mahe Y, Mirey G, Leprince C, Meunier-Bisceuil B, Sorkin A, et al. RLIP76, an effector of the GTAPase Ral, interacts with the AP2 complex: involvement of the Ral pathway in receptor endocytosis. J Cell Sci 2000; 113: 2837–44.
32 Wang Y, Pennock S, Chen X, Wang Z. Endosomal signaling of epidermal growth factor receptor stimulates signal transduction pathways leading to cell survival. Mol Cell Biol 2002; 22: 7279–90.
33 Resat H, Ewald JA, Dixon DA, Wiley HS. An integrated model of epidermal growth factor receptor trafficking and signal transduction. Biophys J 2003; 85: 730–43.
34 Awasthi S, Cheng J, Singhal SS, Saini MK, Pandya U, Pikula S, et al. Novel function of human RLIP76: ATP-dependent transport of glutathione conjugates and doxorubicin. Biochemistry 2000; 39: 9327–34.
35 Drake KJ, Singhal J, Yadav S, Nadkar A, Pungaliya C, Singhal SS, et al. RALBP1/RLIP76 mediates multidrug resistance. Int J Oncol 2007; 30: 139–44.
36 Singhal SS, Singhal J, Nair MP, Lacko AG, Awasthi YC, Awasthi S. Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol 2007; 30: 717–25.
37 Kashatus DF, Lim KH, Brady DC, Pershing NL, Cox AD, Counter CM. RALA and RALBP1 regulate mitochondrial fission at mitosis. Nat Cell Biol 2011; 13: 1108–15.
38 Neel NF, Rossman KL, Martin TD, Hayes TK, Yeh JJ, Der CJ. The RalB small GTAPase mediates formation of invadopodia through a GTAPase-activating protein-independent function of the RalBP1/RLIP76 effector. Mol Cell Biol 2012; 32: 1374–86.
39 Sugihara K, Asano S, Tanaka K, Iwamatsu A, Okawa K, Ohta Y. The exocyst complex binds the small GTAPase RalA to mediate filopodia formation. Nat Cell Biol 2002; 4: 73–8.
40 Moskalenko S, Henry DO, Rosse C, Mirey G, Camonis JH, White MA. The exocyst is a Ral effector complex. Nat Cell Biol 2002; 4: 66–72.
41 Spiczka KS, Yeaman C. Ral-regulated interaction between Sec5 and paxillin targets Exocyst to focal complexes during cell migration. J Cell Sci 2008; 121: 2880–91.
42 Shipitsin M, Feig LA. RalA but not RalB enhances polarized delivery of membrane proteins to the basolateral surface of epithelial cells. Mol Cell Biol 2004; 24: 5746–56.
43 Hazelett CC, Sheff D, Yeaman C. RalA and RalB differentially regulate development of epithelial tight junctions. Mol Cell Biol 2011; 21: 4787–800.
44 Cascone I, Selimoglu R, Ozdemir C, Del Nery E, Yeaman C, White M, et al. Distinct roles of RalA and RalB in the progression of cytokinesis are supported by distinct RalGEFs. EMBO J 2008; 27: 2375–87.
45 Chien Y, Kim S, Bumeister R, Loo YM, Kwon SW, Johnson CL, et al. RalB GTAPase-mediated activation of the Ikapapb family kinase TBK1 couples innate immune signaling to tumor cell survival. Cell 2006; 127: 157–70.
46 Bodemann BO, Orvedahl A, Cheng T, Ram RR, Ou YH, Formstecher E, et al. RalB and the exocyst mediate the cellular starvation response by direct activation of autophagosome assembly. Cell 2011; 144: 253–67.
47 Das A, Gajendra S, Falenta K, Oudin MJ, Peschard P, Feng S, et al. RalA promotes a direct exocyst-Par6 interaction to regulate polarity in neuronal development. J Cell Sci 2014; 127: 686–99.
48 Frankel P, Aronheim A, Kavanagh E, Balda MS, Matter K, Bunney TD, et al. RalA interacts with ZONAB in a cell survival-dependent manner and regulates its transcriptional activity. EMBO J 2005; 24: 54–62.
49 Ohta Y, Suzuki N, Nakamura S, Hartwig JH, Stossel TP. The small GTPase RalA targets filamin to induce filopodia. Proc Natl Acad Sci U S A 1999; 96: 2122–8.
50 Jiang H, Luo QJ, Frankel P, Lu Z, Foster DA, et al. Involvement of Ral GTPase in v-Src-induced phospholipase D activation. Nature 1995; 378: 409–12.
51 Xu L, Salloum D, Saqca M, Yellen P, Perrella B, et al. Phospholipase D mediates nutrient input to mammalian target of rapamycin complex 1 (mTORC1). J Biol Chem 2011; 286: 25477–86.
52 Chien Y, White MA. RAL GTPases are linchpin modulators of human tumour-cell proliferation and survival. EMBO Rep 2003; 4: 800–6.
53 Oxford G, Owens CR, Titus BJ, Foreman TL, Herlevsen MC, Smith SC, et al. RalA and RalB: antagonistic relatives in cancer cell migration. Cancer Res 2005; 65: 7111–20.
54 Lim KH, O`Hayer K, Adam SJ, Kendall SD, Campbell PM, Der CJ, et al. Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells. Curr Biol 2006; 16: 2385–94.
55 Guin S, Ru Y, Wynes MW, Mishra R, Lu X, Owens C, et al. Contributions of KRAS and RAL in non-small-cell lung cancer growth and progression. J Thorac Oncol 2013; 8: 1492–501.
56 Smith SC, Oxford G, Baras AS, Owens C, Havaleshko D, Brautigan DL, et al. Expression of ral GTPases, their effectors, and activators in human bladder cancer. Clin Cancer Res 2007; 13: 3803–13.
57 Ezzeldin M, Borrego-Diaz E, Taha M, Esfandyari T, Wise AL, Peng W, et al. RalA signaling pathway as a therapeutic target in hepatocellular carcinoma (HCC). Mol Oncol 2014; 8: 1042–53.
58 Wang K, Terai K, Peng W, Rouyianian A, Liu J, Roby JF, et al. The role of RalA in biology and therapy of ovarian cancer. Oncotarget 2013 Dec 10. [Epub ahead of print]
59 Zipfel PA, Brady DC, Kashatus DF, Ancrile BD, Tyler DS, Counter CM. Ral activation promotes melanoma gene expression. Oncogene 2010; 29: 4859–64.
60 Male H, Patel V, Jacob MA, Borrego-Diaz E, Wang K, Young DA, et al. Inhibition of RalA signaling pathway in treatment of non-small cell lung cancer. Lung Cancer 2012; 77: 252–9.
61 Yan C, Liu D, Li L, Wempe MF, Guin S, Khanna M, et al. Discovery and characterization of small molecules that target the GTPase Ral. Nature 2014; 515: 443–7.
62 Lim KH, Brady DC, Kashatus DF, Ancrile BB, Der CJ, Cox AD, et al. Aurora-A phosphorylates, activates, and relocalizes the small GTPase RalA. Mol Cell Biol 2010; 30: 508–23.
63 Kidd AR 3rd, Snider JL, Martin TD, Graboski SF, Der CJ, Cox AD, et al. Ras-related small GTPases RaA and RB regulate cellular survival after ionizing radiation. Int J Radiat Oncol Biol Phys 2010; 78: 205–12.
64 Smith SC, Theodorescu D. The Ral GTPase pathway in metastatic bladder cancer: key mediator and therapeutic target. Urol Oncol 2009; 27: 42–7.
65 Wang H, Owens C, Chandra N, Conaway MR, Brautigan DL, Theodorescu D. Phosphorylation of RalB is important for bladder cancer cell growth and metastasis. Cancer Res 2010; 70: 8760–9.
66 Martin TD, Samuel JC, Routh ED, Der CJ, Yeh JJ. Activation and involvement of Ral GTPases in colorectal cancer. Cancer Res 2011; 71: 206–15.
67 Zhu X, Li Y, Luo X, Fei J. Inhibition of small GTPase RalA regulates growth and arsenic-induced apoptosis in chronic myeloid leukemia (CML) cells. Cell Signal 2012; 24: 1134–40.
68 Sowalsky AG, Alt-Holland A, Shamas Y, Garlick JA, Feig LA. RalA function in dermal fibroblasts is required for the progression of squamous cell carcinoma of the skin. Cancer Res 2011; 71: 758–67.
69 Bodempudi Y, Yamoutpoor F, Pan W, Dudek AZ, Esfandyari T, Piedra M, et al. Ral overactivation in malignant peripheral nerve sheath tumors. Mol Cell Biol 2009; 29: 3964–74.
70 Yin J, Pollock C, Tracy K, Chock M, Martin P, Oberst M, et al. Activation of the RasGEF/Ral pathway promotes prostate cancer metastasis to bone. Mol Cell Biol 2007; 27: 7538–50.
71 Li Z, Zhang Y, Kim WJ, Daaka Y. PGE2 promotes renal carcinoma cell invasion through activated RalA. Oncogene 2013; 32: 1408–15.
72 Hamada M, Miki T, Iwai S, Shimizu H, Yura Y. Involvement of RhoA and RalB in geranylgeranylation transferase I inhibitor-mediated inhibition of proliferation and migration of human oral squamous cell carcinoma cells. Cancer Chemother Pharmacol 2011; 68: 559–69.
73 de Gorter DJ, Reijmers RM, Beuling EA, Naber HP, Kuil A, Kersten MJ, et al. The small GTPase Ral mediates SDF-1-induced migration of B cells and multiple myeloma cells. Blood 2008; 111: 3364–72.
74 Smith SC, Baras AS, Owens CR, Dancik G, Theodorescu D. Transcriptional signatures of Ral GTPase are associated with aggressive clinicopathologic characteristics in human cancer. Cancer Res 2012; 72: 3480–91.
75 Huang L, Hofer F, Martin GS, Kim SH. Structural basis for the interaction of Ras with RalGDS. Nat Struct Biol 1998; 5: 422–6.
76 Kim EY, Kim A, Kim SK, Kim HJ, Chang J, Ahn CM, et al. KRAS oncogene substitutions in Korean NSCLC patients: clinical implication and relationship with pAKT and RalGTPase expression. Lung Cancer 2014; 85: 299–305.
77 Bae NC, Chae MH, Lee MH, Kim KM, Lee EB, Kim CH, et al. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients. Cancer Genet Cytogenet 2007; 173: 107–13.
78 Kim YT, Kim TY, Lee DS, Park SJ, Park JY, Seo SJ, et al. Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung. Lung Cancer 2008; 59: 111–8.
79 Soung YH, Lee JW, Kim SY, Seo SH, Park WS, Nam SW, et al. Mutation analysis of EGFR and K-RAS genes in lung adenocarcinomas. Virchows Arch 2005; 446: 483–8.
80 Jang TW, Oak CH, Chang HK, Suh SJ, Jung MH. EGFR and KRAS mutations in patients with adenocarcinoma of the lung. Korean J Intern Med 2009; 24: 48–54.
81 Roberts PJ, Stinchcombe TE. KRAS mutation: should we test for it, and does it matter? J Clin Oncol 2013; 31: 1112–21.